Clinical overview of promising nonthienopyridine antiplatelet agents

被引：40

作者：

Angiolillo, Dominick J. ^{[1
]}

Guzman, Luis A. ^{[1
]}

机构：

[1] Univ Florida, Coll Med, Div Cardiol, Jacksonville, FL USA

来源：

AMERICAN HEART JOURNAL | 2008年 / 156卷 / 02期

关键词：

D O I：

10.1016/j.ahj.2008.06.006

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Three novel nonthienopyridine antiplatelet agents-cangrelor, ticagrelor (AZD6140), and SCH 530348-are in advanced clinical testing in patients with coronary artery disease. Cangrelor and ticagrelor are direct and reversible inhibitors of the platelet adenosine 5'-diphosphate P2Y(12) receptor, whereas SCH 530348 is a thrombin receptor antagonist. Clinical data available to date for each of these compounds suggest that they have safety and efficacy profiles that will be advantageous to patients with acute coronary syndromes or undergoing percutaneous intervention. We review the clinical features of these new platelet inhibition therapies.

引用

页码：S23 / S28

页数：6

共 16 条

[1] ADP receptor antagonism - What's in the pipeline? [J].

Angiolillo, Dominick J. .

AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2007, 7 (06) :423-432

[2] Variability in individual responsiveness to clopidogrel - Clinical implications, management, and future perspectives [J].

Angiolillo, Dominick J. ;

Fernandez-Ortiz, Antonio ;

Bernardo, Esther ;

Alfonso, Fernando ;

Macaya, Carlos ;

Bass, Theodore A. ;

Costa, Marco A. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (14) :1505-1516

[3]

[Anonymous], 2004, HAEMATOLOGICA, V89, P14

[4] Safety, tolerability, and initial efficacy of AZD6140, the first reversivle oral adenosine diphosphate receptor antagonist, compared with clopidigrel, in patients with non-ST-segment elevation acute coronary syndrome - Primary results of the DISPERSE-2 trial [J].

Cannon, Christopher P. ;

Husted, Steen ;

Harrington, Robert A. ;

Scirica, Benjamin M. ;

Emanuelsson, Hakan ;

Storey, Robert F. .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (19) :1844-1851

[5] Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention:: Results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial [J].

Greenbaum, AB ;

Grines, CL ;

Bittl, JA ;

Becker, RC ;

Kereiakes, DJ ;

Gilchrist, IC ;

Clegg, J ;

Stankowski, JE ;

Grogan, DR ;

Harrington, RA ;

Emanuelsson, H ;

Weaver, WD .

AMERICAN HEART JOURNAL, 2006, 151 (03) :689.e1-689.e10

[6] Intravenous adenosine diphosphate P2T platelet receptor antagonism as an adjunct to fibrinolysis for acute myocardial infarction [J].

Greenbaum, AB ;

Ohman, EM ;

Gibson, MS ;

Borzak, SL ;

LeMay, M ;

Lu, M ;

Stebbins, AL ;

Emanuelsson, H ;

Weaver, WD .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (05) :281A-281A

[7] Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis:: a double-blind comparison to clopidogrel with aspirin [J].

Husted, S ;

Emanuelsson, H ;

Heptinstall, S ;

Sandset, PM ;

Wickens, M ;

Peters, G .

EUROPEAN HEART JOURNAL, 2006, 27 (09) :1038-1047

[8] Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction [J].

Jacobsson, F ;

Swahn, E ;

Wallentin, L ;

Dellborg, M .

CLINICAL THERAPEUTICS, 2002, 24 (05) :752-765

[9]

Jarvis GE, 1999, BLOOD, V94, p22A

[10]

Kosoglou T., 2005, CIRCULATION S, V112, pI

← 1 2 →